8-K

                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D. C. 20549



                            FORM 8-K

                         CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
                              1934



Date of Report (Date of earliest event reported):  July 24, 2003



                      HEMACARE CORPORATION
     (Exact Name of Registrant as Specified in its Charter)



                           CALIFORNIA
         (State or other jurisdiction of incorporation)



      000-15223                          95-3280412
(Commission File No.)         (IRS Employer Identification No.)



                       21101 Oxnard Street
                    Woodland Hills, CA 91367
      (Address of principal executive offices and Zip Code)



Registrant's telephone number, including area code: (818) 226-1968

                              -1-



ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

The text of a press release dated July 24, 2003, issued by
HemaCare Corporation ("HemaCare") announcing that Wm. Andrew
Heaton has resigned from the Company's Board of Directors and
that the number of Board seats has been reduced from six to
five is attached as Exhibit 99.1 hereto and is incorporated by
reference herein.


ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number   Description

99.1             Press Release issued by HemaCare, dated
                 July 24, 2003


                           SIGNATURES

Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the registrant has duly caused this report to be signed  on
its behalf by the undersigned hereunto duly authorized.



Date: July 24, 2003           HEMACARE CORPORATION

                             /s/ Judi Irving
                             ----------------------------
                              Judi Irving,
                              Chief Executive Officer




                          EXHIBIT INDEX

Exhibit Number   Description
- --------------   -----------
99.1             Press Release issued by HemaCare, dated July
                 24, 2003


                                 -2-

EX-99

                             [LOGO}



                     N E W S   R E L E A S E



For Immediate Release

Contact:  HemaCare Corporation
          JoAnn Mannise, Director of Investor Relations
          Phone: 877.310.0717
          Website: www.hemacare.com


  WM. ANDREW HEATON RESIGNS FROM HEMACARE'S BOARD OF DIRECTORS

- -----------------------------------------------------------------

     Los  Angeles, CA, July 24, 2003 - HemaCare Corporation  (OTC
Bulletin Board: HEMA) announced today that Dr. Wm. Andrew  Heaton
has resigned from its Board of Directors.  Dr. Heaton stated that
unexpected changes in other professional commitments required his
withdrawal.

     The Company also announced that it has reduced the number of
Board seats from six to five.

                   About HemaCare Corporation

      Founded  in 1978, HemaCare is a national provider of  blood
products  and  services  and  the only  publicly  traded  company
engaged  in the blood services industry in the U.S.  HemaCare  is
licensed by the FDA and accredited by the American Association of
Blood  Banks.   The Company focuses on providing cost  effective,
high  quality  solutions  to  the  blood-related  needs  of  U.S.
hospitals.


This  press  release  may  contain  "forward-looking  statements"
within  the  meaning  of  the  term  in  the  Private  Securities
Litigation Reform Act of 1995 (Section 27A of the Securities  Act
of  1933,  as amended, and Section 21E of the Securities Exchange
Act  of  1934, as amended).  Additional written or oral  forward-
looking  statements may be made by the Company from  time-to-time
in  filings  with  the  Securities  and  Exchange  Commission  or
otherwise.   Statements contained herein that are not  historical
facts  are forward-looking statements pursuant to the safe harbor
provisions  referenced  above.   Forward-looking  statements  are
inherently  subject  to  risks and uncertainties  some  of  which
cannot  be predicted or quantified.  Such risks and uncertainties
include,  without  limitation, the risks  and  uncertainties  set
forth from time-to-time in reports filed by the Company with  the
Securities   and  Exchange  Commission.   Although  the   Company
believes  that the expectations reflected in such forward-looking
statements  are  reasonable, it can give no assurance  that  such
expectations  will  prove  to be correct.   Consequently,  future
events and actual results could differ materially from those  set
forth  in,  or  contemplated  by, the forward-looking  statements
contained  herein.   The  Company  undertakes  no  obligation  to
publicly release any revision to these forward-looking statements
made to reflect events or circumstances after the date hereof.

                               ###